Quanterix Corp (QTRX) Stock Analysis and Metrics

Quanterix

NASDAQ: QTRX

$3.69 ▼ -0.23 (-5.87%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap184.16 Mn

P/E-1.77

P/S1.27

Div. Yield0.00

ROIC (Qtr)-1.49

Revenue Growth (1y) (Qtr)20.05

Add ratio to table…

About

Quanterix Corporation is a life sciences company focused on accelerating biomarker breakthroughs from discovery to diagnostics through its ultrasensitive detection platforms. The company’s core Simoa technology enables detection of protein biomarkers at femtomolar concentrations in blood serum and other fluids, far surpassing the sensitivity of conventional immunoassays. Complementing this, Quanterix Spatial Biology solutions allow multiplexed protein analysis at single cell resolution within intact tissue sections, preserving spatial context and cellular architecture. Together these platforms support research in neurology, oncology, immunology and inflammation and have been cited in over six thousand scientific publications. As of the end of 2025 Quanterix reported an installed base of more than two thousand five hundred instruments worldwide, reflecting broad adoption among academic research labs contract research organizations and biopharmaceutical firms. The company continues to invest in next generation instrument development and assay menu expansion to address emerging diagnostic opportunities.

Quanterix generates revenue from three principal streams. First, the sale of its Simoa and Spatial Biology instruments, including the HD-X SR-X SP-X PhenoCycler and PhenoImager platforms, contributes upfront capital receipts. Second, recurring revenue comes from the sale of assay kits, consumables, and reagents that customers use to run tests on those instruments, covering neurology, oncology, immunology, and inflammation biomarker panels. Third, the company provides contract research services and clinical laboratory testing through its CLIA certified Accelerator Laboratory, offering LDTs such as LucentAD Complete, Simoa NfL, and p Tau assays, as well as extended warranty and service contracts on its installed base of equipment. Additionally, Quanterix earns income from licensing its proprietary bead based and planar array technologies to third parties and from collaborative development agreements with pharmaceutical partners. This diversified revenue model supports steady cash flow while enabling reinvestment in research development and commercial expansion.

Quanterix occupies a leading niche in the ultrasensitive biomarker detection market, competing with established players such as Bio Techne, MesoScale Discovery, 10x Genomics, Vizgen, Bruker, Miltenyi Biotec, and Standard BioTools. The company’s competitive advantages stem from its femtomolar sensitivity, multiplexing capabilities, and proprietary Simoa bead based and planar array technologies that enable detection of low abundance proteins invisible to conventional assays. Its Spatial Biology platforms further differentiate the offering by delivering single cell protein mapping within intact tissue, a capability not widely available among rivals. Quanterix also benefits from a strong intellectual property portfolio, a growing installed base of over two thousand five hundred instruments, and a reputation for data accuracy and reproducibility that has been validated in thousands of peer reviewed publications. These factors together support its positioning as a trusted partner for academic research, contract research organizations, and biopharmaceutical companies seeking innovative biomarker solutions.

Quanterix serves a diverse customer base that includes research laboratories, contract research organizations, academic institutions, and biopharmaceutical companies engaged in drug discovery and development. The company also provides clinical laboratory testing services to hospital networks and reference labs, with partnerships covering more than twenty five major healthcare institutions across the United States and Europe as of the end of 2025. Through its Accelerator Laboratory, Quanterix offers LDTs such as LucentAD Complete and Simoa NfL to neurologists, oncologists, and immunologists seeking noninvasive diagnostic information. Additionally, the subsidiary UmanDiagnostics supplies NfL antibodies and ELISA kits to distributors and end users worldwide, further broadening the reach of its biomarker technologies. This mix of research focused and clinical oriented customers supports both upstream biomarker discovery and downstream diagnostic adoption.

Investment Thesis

▲ Bull case

The partnership with Tempus AI integrates LucentAD Complete into electronic health record systems at select partner health systems as part of the Tempus Next program. This collaboration creates a direct channel for clinicians to order the blood based Alzheimer test. Management expects FDA clearance for LucentAD Complete in the second half of the year and the Tempus link will facilitate rapid adoption once clearance is obtained. The combination of regulatory progress and a built in distribution network could unlock revenue upside that is not fully reflected in current guidance.
The strategic focus on the Simoa HD X platform includes plans to file for IVD status with the FDA in 2027 and ongoing upgrades to improve reliability and performance. These enhancements will serve both research customers who increasingly request IVD solutions for clinical trials and lab partners interested in a distributed diagnostic model. By advancing the HD X platform toward regulatory approval Quanterix builds optionality that could expand its addressable market beyond pure research tools. The market may be underestimating the long term value of this regulatory pathway.
Commercial investments include an expanded lead generation team and new market development leaders designed to improve outbound targeting and increase net new opportunities. The company also plans to leverage Thermo Fisher s digital distribution capabilities to reduce manual quoting and improve online access for customers. Early data from the first three weeks of the quarter show a market difference in net new opportunity generation. These initiatives are expected to translate into higher conversion rates and stronger revenue growth in the second half of the fiscal year.
Annualized cost synergies from the Akoya acquisition have reached eighty five million dollars and are already delivering non GAAP gross margin above fifty%. The company ended Q1 with one hundred two million six hundred thousand dollars in cash and no debt providing a solid balance sheet to fund growth initiatives. Management expects to maintain operating discipline while investing in Alzheimer diagnostics and commercial expansion. This financial flexibility supports the path to cash flow break even without jeopardizing liquidity.
Intensified pharma partnership efforts are being led by a new senior leader with extensive diagnostics and payer experience who will engage directly with pharmaceutical clients to tailor solutions. Simultaneously a salesforce transformation is underway that adds more feet on the street and refocuses the team on differentiation such as superior sensitivity and reproducibility. These actions aim to reverse the observed sixteen% decline in academic revenue and thirty three% decline in pharma revenue on a pro forma basis. If successful the company could capture additional share as end markets stabilize.

The partnership with Tempus AI integrates LucentAD Complete into electronic health record systems at select partner health systems as part of the Tempus Next program. This collaboration creates a direct channel for clinicians to order the blood based Alzheimer test. Management expects FDA clearance for LucentAD Complete in the second half of the year and the Tempus link will facilitate rapid adoption once clearance is obtained. The combination of regulatory progress and a built in distribution network could unlock revenue upside that is not fully reflected in current guidance.
The strategic focus on the Simoa HD X platform includes plans to file for IVD status with the FDA in 2027 and ongoing upgrades to improve reliability and performance. These enhancements will serve both research customers who increasingly request IVD solutions for clinical trials and lab partners interested in a distributed diagnostic model. By advancing the HD X platform toward regulatory approval Quanterix builds optionality that could expand its addressable market beyond pure research tools. The market may be underestimating the long term value of this regulatory pathway.
Commercial investments include an expanded lead generation team and new market development leaders designed to improve outbound targeting and increase net new opportunities. The company also plans to leverage Thermo Fisher s digital distribution capabilities to reduce manual quoting and improve online access for customers. Early data from the first three weeks of the quarter show a market difference in net new opportunity generation. These initiatives are expected to translate into higher conversion rates and stronger revenue growth in the second half of the fiscal year.
Annualized cost synergies from the Akoya acquisition have reached eighty five million dollars and are already delivering non GAAP gross margin above fifty%. The company ended Q1 with one hundred two million six hundred thousand dollars in cash and no debt providing a solid balance sheet to fund growth initiatives. Management expects to maintain operating discipline while investing in Alzheimer diagnostics and commercial expansion. This financial flexibility supports the path to cash flow break even without jeopardizing liquidity.
Intensified pharma partnership efforts are being led by a new senior leader with extensive diagnostics and payer experience who will engage directly with pharmaceutical clients to tailor solutions. Simultaneously a salesforce transformation is underway that adds more feet on the street and refocuses the team on differentiation such as superior sensitivity and reproducibility. These actions aim to reverse the observed sixteen% decline in academic revenue and thirty three% decline in pharma revenue on a pro forma basis. If successful the company could capture additional share as end markets stabilize.

▼ Bear case

Reported revenue growth of twenty% was driven primarily by the Akoya acquisition while organic revenue declined twenty one%. Simoa revenue fell twenty one% on an organic basis and spatial revenue dropped twenty six% year over year. This underlying weakness suggests that end market demand remains challenged and that the company s top line is still dependent on inorganic contributions. Investors may be overestimating the ability of recent commercial initiatives to quickly reverse these trends.
LucentAD Complete remains a research use only test and has not yet secured FDA clearance for diagnostic use. Management anticipates clearance in the second half but the timeline depends on successful completion of clinical utility studies that are still underway. Reimbursement pathways for a blood based Alzheimer biomarker are unproven and payer adoption may be slower than expected. Any delay in clearance or reimbursement would postpone the expected revenue contribution from the diagnostics business.
Pharma revenue declined thirty three% on a pro forma basis reflecting fewer large accelerator projects and reduced spatial instrument placements. Despite the addition of a dedicated diagnostics leader and expanded market development team the sales cycles for pharma partnerships are typically long and competitive. There is no guarantee that the increased investment will translate into near term order growth or that the company will regain lost share in the pharma end market.
Adjusted cash usage for the quarter was fourteen point seven million dollars after excluding four point two million dollars in one time items. To reach cash flow break even by the Q4 FY26 the company will need to substantially reduce its quarterly cash burn while maintaining investment in growth initiatives. Continued operating losses raise questions about the sustainability of the current cash position if revenue acceleration does not materialize as expected.
The impending departure of Chief Financial Officer Vandana Sriram scheduled for June fifteen two thousand twenty six removes a key architect of the company s cost discipline and cash management framework. Simultaneously the inducement grant to the new Chief Operating Officer Anthony Catalano represents a significant equity dilution and may signal uncertainty about integration leadership. Leadership transitions at this stage could disrupt ongoing initiatives and impair financial oversight.

Reported revenue growth of twenty% was driven primarily by the Akoya acquisition while organic revenue declined twenty one%. Simoa revenue fell twenty one% on an organic basis and spatial revenue dropped twenty six% year over year. This underlying weakness suggests that end market demand remains challenged and that the company s top line is still dependent on inorganic contributions. Investors may be overestimating the ability of recent commercial initiatives to quickly reverse these trends.
LucentAD Complete remains a research use only test and has not yet secured FDA clearance for diagnostic use. Management anticipates clearance in the second half but the timeline depends on successful completion of clinical utility studies that are still underway. Reimbursement pathways for a blood based Alzheimer biomarker are unproven and payer adoption may be slower than expected. Any delay in clearance or reimbursement would postpone the expected revenue contribution from the diagnostics business.
Pharma revenue declined thirty three% on a pro forma basis reflecting fewer large accelerator projects and reduced spatial instrument placements. Despite the addition of a dedicated diagnostics leader and expanded market development team the sales cycles for pharma partnerships are typically long and competitive. There is no guarantee that the increased investment will translate into near term order growth or that the company will regain lost share in the pharma end market.
Adjusted cash usage for the quarter was fourteen point seven million dollars after excluding four point two million dollars in one time items. To reach cash flow break even by the Q4 FY26 the company will need to substantially reduce its quarterly cash burn while maintaining investment in growth initiatives. Continued operating losses raise questions about the sustainability of the current cash position if revenue acceleration does not materialize as expected.
The impending departure of Chief Financial Officer Vandana Sriram scheduled for June fifteen two thousand twenty six removes a key architect of the company s cost discipline and cash management framework. Simultaneously the inducement grant to the new Chief Operating Officer Anthony Catalano represents a significant equity dilution and may signal uncertainty about integration leadership. Leadership transitions at this stage could disrupt ongoing initiatives and impair financial oversight.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password